MUC16 and ovarian carcinoma: In patients with newly diagnosed FIGO stage II to IV ovarian cancer, the serum CA-125 level at 3 months after the end of primary treatment showed the best prediction of the overall survival probability at 24, 36, and 48 months compared to various measures of the CA-125 decrease rate.